Editas Medicine (EDIT) Misses Q4 EPS by 9c

Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.84), $0.09 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $3.67 million versus the consensus estimate of $4.13 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance